Oxidation resistant coatings for ceramic matrix composite components

Corrosion resistant Ca{sub 0.6}Mg{sub 0.4}Zr{sub 4}(PO{sub 4}){sub 6} (CMZP) and Ca{sub 0.5}Sr{sub 0.5}Zr{sub 4}(PO{sub 4}){sub 6} (CS-50) coatings for fiber-reinforced SiC-matrix composite heat exchanger tubes have been developed. Aqueous slurries of both oxides were prepared with high solids loading. One coating process consisted of dipping the samples in a slip. A tape casting process has also been created that produced relatively thin and dense coatings covering a large area. A processing technique was developed, utilizing a pre-sintering step, which produced coatings with minimal cracking

Design and Initial Development of Monolithic Cross-Flow Ceramic Hot-Gas Filters

Advanced, coal-fueled, power generation systems utilizing pressurized fluidized bed combustion (PFBC) and integrated gasification combined cycle (IGCC) technologies are currently being developed for high-efficiency, low emissions, and low-cost power generation. In spite of the advantages of these promising technologies, the severe operating environment often leads to material degradation and loss of performance in the barrier filters used for particle entrapment. To address this problem, LoTEC Inc., and Oak Ridge National Laboratory are jointly designing and developing a monolithic cross-flow ceramic hot-gas filter. The filter concept involves a truly monolithic cross-flow design that is resistant to delamination, can be easily fabricated, and offers flexibility of geometry and material make-up. During Phase I of the program, a thermo-mechanical analysis was performed to determine how a cross-flow filter would respond both thermally and mechanically to a series of thermal and mechanical loads. The cross-flow filter mold was designed accordingly, and the materials selection was narrowed down to Ca{sub 0.5}Sr{sub 0.5}Zr{sub 4}P{sub 6}O{sub 24} (CS-50) and 2Al{sub 2}O{sub 3}-3SiO{sub 2} (mullite). A fabrication process was developed using gelcasting technology and monolithic cross-flow filters were fabricated. The program focuses on obtaining optimum filter permeability and testing the corrosion resistance of the candidate materials

New insights into landslide processes around volcanic islands from Remotely Operated Vehicle (ROV) observations offshore Montserrat

Submarine landslide deposits have been mapped around many volcanic islands, but interpretations of their structure, composition, and emplacement are hindered by the challenges of investigating deposits directly. Here we report on detailed observations of four landslide deposits around Montserrat collected by Remotely Operated Vehicles, integrating direct imagery and sampling with sediment core and geophysical data. These complementary approaches enable a more comprehensive view of large-scale mass-wasting processes around island-arc volcanoes than has been achievable previously. The most recent landslide occurred at 11.5–14 ka (Deposit 1; 1.7 km3) and formed a radially spreading hummocky deposit that is morphologically similar to many subaerial debris-avalanche deposits. Hummocks comprise angular lava and hydrothermally altered fragments, implying a deep-seated, central subaerial collapse, inferred to have removed a major proportion of lavas from an eruptive period that now has little representation in the subaerial volcanic record. A larger landslide (Deposit 2; 10 km3) occurred at ∼130 ka and transported intact fragments of the volcanic edifice, up to 900 m across and over 100 m high. These fragments were rafted within the landslide, and are best exposed near the margins of the deposit. The largest block preserves a primary stratigraphy of subaerial volcanic breccias, of which the lower parts are encased in hemipelagic mud eroded from the seafloor. Landslide deposits south of Montserrat (Deposits 3 and 5) indicate the wide variety of debris-avalanche source lithologies around volcanic islands. Deposit 5 originated on the shallow submerged shelf, rather than the terrestrial volcanic edifice, and is dominated by carbonate debris

Recommendations for laboratory workflow that better support centralised amalgamation of genomic variant data: findings from CanVIG-UK national molecular laboratory survey.

BACKGROUND: National and international amalgamation of genomic data offers opportunity for research and audit, including analyses enabling improved classification of variants of uncertain significance. Review of individual-level data from National Health Service (NHS) testing of cancer susceptibility genes (2002-2023) submitted to the National Disease Registration Service revealed heterogeneity across participating laboratories regarding (1) the structure, quality and completeness of submitted data, and (2) the ease with which that data could be assembled locally for submission. METHODS: In May 2023, we undertook a closed online survey of 51 clinical scientists who provided consensus responses representing all 17 of 17 NHS molecular genetic laboratories in England and Wales which undertake NHS diagnostic analyses of cancer susceptibility genes. The survey included 18 questions relating to 'next-generation sequencing workflow' (11), 'variant classification' (3) and 'phenotypical context' (4). RESULTS: Widely differing processes were reported for transfer of variant data into their local LIMS (Laboratory Information Management System), for the formatting in which the variants are stored in the LIMS and which classes of variants are retained in the local LIMS. Differing local provisions and workflow for variant classifications were also reported, including the resources provided and the mechanisms by which classifications are stored. CONCLUSION: The survey responses illustrate heterogeneous laboratory workflow for preparation of genomic variant data from local LIMS for centralised submission. Workflow is often labour-intensive and inefficient, involving multiple manual steps which introduce opportunities for error. These survey findings and adoption of the concomitant recommendations may support improvement in laboratory dataflows, better facilitating submission of data for central amalgamation

Malaria eradication: the economic, financial and institutional challenge

Malaria eradication raises many economic, financial and institutional challenges. This paper reviews these challenges, drawing on evidence from previous efforts to eradicate malaria, with a special focus on resource-poor settings; summarizes more recent evidence on the challenges, drawing on the literature on the difficulties of scaling-up malaria control and strengthening health systems more broadly; and explores the implications of these bodies of evidence for the current call for elimination and intensified control

Anxiety Disorders in Williams Syndrome Contrasted with Intellectual Disability and the General Population: A Systematic Review and Meta-Analysis

Individuals with specific genetic syndromes associated with intellectual disability (ID), such as Williams syndrome (WS), are at increased risk for developing anxiety disorders. A systematic literature review identified sixteen WS papers that could generate pooled prevalence estimates of anxiety disorders for WS. A meta-analysis compared these estimates with prevalence estimates for the heterogeneous ID population and the general population. Estimated rates of anxiety disorders in WS were high. WS individuals were four times more likely to experience anxiety than individuals with ID, and the risk was also heightened compared to the general population. The results provide further evidence of an unusual profile of high anxiety in WS

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH,non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2–F3, or F1 with at least oneaccompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpointsfor the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2–F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1–F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2–F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1–F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes

Germline mismatch repair (MMR) gene analyses from English NHS regional molecular genomics laboratories 1996–2020: development of a national resource of patient-level genomics laboratory records

Objective To describe national patterns of National Health Service (NHS) analysis of mismatch repair (MMR) genes in England using individual-level data submitted to the National Disease Registration Service (NDRS) by the NHS regional molecular genetics laboratories. Design Laboratories submitted individual-level patient data to NDRS against a prescribed data model, including (1) patient identifiers, (2) test episode data, (3) per-gene results and (4) detected sequence variants. Individualised per-laboratory algorithms were designed and applied in NDRS to extract and map the data to the common data model. Laboratory-level MMR activity audit data from the Clinical Molecular Genetics Society/Association of Clinical Genomic Science were used to assess early years’ missing data. Results Individual-level data from patients undergoing NHS MMR germline genetic testing were submitted from all 13 English laboratories performing MMR analyses, comprising in total 16 722 patients (9649 full-gene, 7073 targeted), with the earliest submission from 2000. The NDRS dataset is estimated to comprise >60% of NHS MMR analyses performed since inception of NHS MMR analysis, with complete national data for full-gene analyses for 2016 onwards. Out of 9649 full-gene tests, 2724 had an abnormal result, approximately 70% of which were (likely) pathogenic. Data linkage to the National Cancer Registry demonstrated colorectal cancer was the most frequent cancer type in which full-gene analysis was performed. Conclusion The NDRS MMR dataset is a unique national pan-laboratory amalgamation of individual-level clinical and genomic patient data with pseudonymised identifiers enabling linkage to other national datasets. This growing resource will enable longitudinal research and can form the basis of a live national genomic disease registry. Data availability statement Data are available upon reasonable request. Data may be obtained from a third party and are not publicly available. All data relevant to the study are included in the article or uploaded as supplementary information. All summary data relevant to the study are included in the article or uploaded as online supplementary information. Individual level data detailed in this study are held within NHS Digital with access available on application